Log in

Vaccinex Stock Price, Forecast & Analysis (NASDAQ:VCNX)

$4.60
-0.15 (-3.16 %)
(As of 11/22/2019 08:00 AM ET)
Today's Range
$4.60
Now: $4.60
$4.80
50-Day Range
$4.56
MA: $5.62
$6.99
52-Week Range
$3.32
Now: $4.60
$8.49
Volume800 shs
Average Volume2,259 shs
Market Capitalization$68.36 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCNX
CUSIPN/A
CIKN/A
Phone585-271-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$720,000.00
Book Value$0.26 per share

Profitability

Net Income$-29,520,000.00
Net Margins-4,740.03%

Miscellaneous

Employees44
Market Cap$68.36 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive VCNX News and Ratings via Email

Sign-up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter.


Vaccinex (NASDAQ:VCNX) Frequently Asked Questions

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

How were Vaccinex's earnings last quarter?

Vaccinex Inc (NASDAQ:VCNX) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.10. The firm earned $0.40 million during the quarter. Vaccinex had a negative return on equity of 585.69% and a negative net margin of 4,740.03%. View Vaccinex's Earnings History.

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Vaccinex.

What price target have analysts set for VCNX?

1 brokerages have issued 1 year price objectives for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next year. This suggests a possible upside of 378.3% from the stock's current price. View Analyst Price Targets for Vaccinex.

What is the consensus analysts' recommendation for Vaccinex?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaccinex.

Has Vaccinex been receiving favorable news coverage?

News stories about VCNX stock have been trending negative on Friday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaccinex earned a news impact score of -2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Vaccinex.

Are investors shorting Vaccinex?

Vaccinex saw a decrease in short interest during the month of October. As of October 15th, there was short interest totalling 62,600 shares, a decrease of 9.3% from the September 15th total of 69,000 shares. Based on an average daily volume of 6,300 shares, the short-interest ratio is currently 9.9 days. Approximately 1.9% of the company's stock are short sold. View Vaccinex's Current Options Chain.

Who are some of Vaccinex's key competitors?

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Whiting Canadian (KOG), Whiting Petroleum (WLL), Hollywood Media (HOLL), Whiting USA Trust II (WHZT), Exelixis (EXEL), Compugen (CGEN), Netflix (NFLX), Compugroup Medical (COP), Applegreen (APGN) and Hollywood Bowl Group (BOWL).

Who are Vaccinex's key executives?

Vaccinex's management team includes the folowing people:
  • Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 73)
  • Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)
  • Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)
  • Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
  • Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45)

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Oppenheimer & Co. Inc. (0.19%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View Institutional Ownership Trends for Vaccinex.

Which institutional investors are buying Vaccinex stock?

VCNX stock was bought by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc.. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View Insider Buying and Selling for Vaccinex.

How do I buy shares of Vaccinex?

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $4.60.

How big of a company is Vaccinex?

Vaccinex has a market capitalization of $68.36 million and generates $720,000.00 in revenue each year. The company earns $-29,520,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Vaccinex employs 44 workers across the globe.View Additional Information About Vaccinex.

What is Vaccinex's official website?

The official website for Vaccinex is http://www.vaccinex.com/.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]


MarketBeat Community Rating for Vaccinex (NASDAQ VCNX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Vaccinex and other stocks. Vote "Outperform" if you believe VCNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel